𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?

✍ Scribed by Josef S. Smolen; Daniel Aletaha; Edward Keystone

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
94 KB
Volume
52
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination of infliximab and methotrexa
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
✍ E. William St. Clair; Désirée M. F. M. van der Heijde; Josef S. Smolen; Ravinder 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

## Abstract ## Objective To compare the benefits of initiating treatment with methotrexate (MTX) and infliximab (anti–tumor necrosis factor α [anti‐TNFα] monoclonal antibody) with those of MTX treatment alone in patients with rheumatoid arthritis (RA) of ≤3 years' duration. ## Methods RA patient

Delay to institution of therapy and indu
Delay to institution of therapy and induction of remission using single-drug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis
✍ Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 2 views

## Abstract ## Objective To study the impacts of 1) the delay from the onset of symptoms to the institution of disease‐modifying antirheumatic drug (DMARD) therapy, 2) two treatment strategies (treatment with a combination of DMARDs or with a single drug), and 3) the presence of HLA–DRB1 alleles (

Sulfasalazine is a potent inhibitor of t
Sulfasalazine is a potent inhibitor of the reduced folate carrier: Implications for combination therapies with methotrexate in rheumatoid arthritis
✍ Gerrit Jansen; Joost van der Heijden; Ruud Oerlemans; Willem F. Lems; Ilan Iferg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

## Abstract ## Objective To investigate whether interactions of sulfasalazine (SSZ) with reduced folate carrier (RFC), the dominant cell membrane transporter for natural folates and methotrexate (MTX), may limit the efficacy of combination therapy with MTX and SSZ in patients with rheumatoid arthr

Combination therapy with etanercept and
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
✍ Mark C. Genovese; Stanley Cohen; Larry Moreland; Deborah Lium; Sean Robbins; Ric 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## Objective To determine the potential for additive or synergistic effects of combination therapy with the selective anti–tumor necrosis factor α agent etanercept and the anti–interleukin‐1 agent anakinra. ## Methods Two hundred forty‐four patients in whom rheumatoid arthritis (RA)